Group One Trading
ALLO icon

Group One Trading’s Allogene Therapeutics ALLO Stock Holding History

Group One Trading’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85.7K Buy
41,200
+29,900
+265% +$65.7K ﹤0.01% 4985
2026
Q1 		$27.6K Hold
11,300
– – ﹤0.01% 5738
2025
Q4 		$15.5K Buy
11,300
+7,200
+176% +$9.5K ﹤0.01% 6546
2025
Q3 		$5.08K Sell
4,100
-38,500
-90% -$45.9K ﹤0.01% 7535
2025
Q2 		$48.1K Sell
42,600
-49,300
-54% -$65.5K ﹤0.01% 5608
2025
Q1 		$134K Sell
91,900
-38,500
-30% -$72.6K ﹤0.01% 4366
2024
Q4 		$278K Buy
130,400
+118,600
+1,005% +$293K ﹤0.01% 3656
2024
Q3 		$33K Buy
11,800
+6,700
+131% +$17.9K ﹤0.01% 4929
2024
Q2 		$11.9K Sell
5,100
-66,500
-93% -$196K ﹤0.01% 5549
2024
Q1 		$320K Buy
71,600
+51,900
+263% +$217K ﹤0.01% 3157
2023
Q4 		$63.2K Sell
19,700
-14,000
-42% -$39.7K ﹤0.01% 4874
2023
Q3 		$107K Buy
33,700
+13,900
+70% +$60.9K ﹤0.01% 4394
2023
Q2 		$98.4K Buy
19,800
+17,700
+843% +$95.7K ﹤0.01% 4639
2023
Q1 		$10.4K Hold
2,100
– – ﹤0.01% 5912
2022
Q4 		$13.2K Sell
2,100
-6,800
-76% -$63K ﹤0.01% 5873
2022
Q3 		$96K Sell
8,900
-4,200
-32% -$57.1K ﹤0.01% 4815
2022
Q2 		$149K Buy
13,100
+3,700
+39% +$32.8K ﹤0.01% 4580
2022
Q1 		$86K Sell
9,400
-6,300
-40% -$65.6K ﹤0.01% 5638
2021
Q4 		$234K Buy
15,700
+12,100
+336% +$213K ﹤0.01% 4930
2021
Q3 		$93K Sell
3,600
-5,000
-58% -$119K ﹤0.01% 5975
2021
Q2 		$224K Buy
8,600
+3,200
+59% +$91.3K ﹤0.01% 5123
2021
Q1 		$191K Buy
5,400
+3,400
+170% +$115K ﹤0.01% 5075
2020
Q4 		$50K Buy
2,000
+1,000
+100% +$32.6K ﹤0.01% 4998
2020
Q3 		$38K Sell
1,000
-200
-17% -$7.54K ﹤0.01% 4802
2020
Q2 		$51K Buy
+1,200
New +$43.4K ﹤0.01% 4341
2020
Q1 		– Sell
-1,400
Closed -$36K – 5186
2019
Q4 		$36K Sell
1,400
-800
-36% -$22K ﹤0.01% 4150
2019
Q3 		$60K Buy
2,200
+200
+10% +$5.7K ﹤0.01% 3882
2019
Q2 		$54K Buy
2,000
+700
+54% +$19.5K ﹤0.01% 3730
2019
Q1 		$38K Buy
+1,300
New +$37.7K ﹤0.01% 3691

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Group One Trading's ALLO Position: Q2 2026 in Review

Group One Trading increased its Allogene Therapeutics (ALLO) stake by 100% in Q2 2026, buying an estimated $8.84K and bringing the position to 8,039 shares worth $16.7K. The position accounts for ﹤0.01% of the portfolio, ranked #6122.

Group One Trading first reported a position in ALLO in Q1 2019 and has held it in 22 quarters since. The position peaked at $697K in Q1 2021. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Group One Trading held 8,039 shares of Allogene Therapeutics worth $16.7K as of Q2 2026.
  • Group One Trading bought 4,025 Allogene Therapeutics shares in Q2 2026, an estimated $8.84K.
  • Allogene Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #6122 holding.
  • Group One Trading first reported a position in Allogene Therapeutics in Q1 2019 and has held it in 22 quarters since.
  • Group One Trading's Allogene Therapeutics position peaked at $697K in Q1 2021.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.